Navigation Links
MimiVax Appoints Jerry Jacobs Jr. to Board of Directors; SurVaxM Immunotherapy Partnership Opportunities at BIO International June 19-22, 2017.
Date:6/12/2017

MimiVax, LLC, a cancer immunotherapy company today announced that Jerry Jacobs, Jr, co-CEO of Delaware North has joined its Board of Directors. Mr. Jacobs brings deep entrepreneurial insights and business resources to the company.

Mr. Jacobs is co-CEO of Delaware North, one of the most admired family-owned and operated companies in the world. Delaware North is headquartered in Buffalo, New York and has annual revenues of $3 billion, employing more than 55,000 employees on four continents. The University at Buffalo medical school was recently named the Jacobs School of Medicine and Biomedical Sciences, in recognition of the Mr. Jacobs family’s steadfast support.

MimiVax’s lead immunotherapeutic agent, SurVaxM, is currently in a Phase II multicenter clinical trial, and a recently completed interim data analysis puts the program in great position for continued advancement. MimiVax is looking forward to Mr. Jacobs’ strategic guidance for the company and helping it progress much needed new therapies for brain cancer patients.

MimiVax executives will be discussing partnering opportunities for its lead program SurVaxM, as well as pre-clinical pipeline assets: novel anti-survivin monoclonal antibody and CAR-T based approaches for solid tumors at the annual BIO International Conference, taking place between June 19-22, 2017 at the San Diego Convention Center.

Michael Ciesielski, PhD, Chief Scientific Officer; and Anil Goyal, PhD, VP Business Development will be attending the BIO event and hosting partnership meetings.

BIO International Conference : (http://www.bio.org)
Monday-Thursday June 19-22, 2017 ; San Diego Convention Center, San Diego, CA

About MimiVax: MimiVax is a privately held, clinical-stage immuno-oncology company focused on the development and commercialization of immunotherapeutics and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Cancer Institute that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to break immune tolerance and stimulate immune responses to control tumor growth and recurrence.

About SurVaxM: SurVaxM, our lead immunotherapeutic product, has demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM is currently being evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma at five cancer centers: Roswell Park Cancer Institute, Cleveland Clinic, Dana-Farber Cancer Institute, Mass General and Beth Israel Deaconess Hospitals. Also a Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer) is ongoing at Roswell Park.

Read the full story at http://www.prweb.com/releases/mimivax/survaxm/prweb14413751.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PCI Appoints John Davis, PE, to Board
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
4. SOTIO a.s. Appoints Chiltern International
5. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
6. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
9. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
10. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
11. TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... August 08, 2018 , ... InTouchMD , the ... announced that they will be exhibiting at Biotech Week Boston , September 4th ... showcasing its Pulse platform, healthcare’s most powerful all in one marketing solution. ...
(Date:8/9/2018)... MAss. (PRWEB) , ... August 09, 2018 , ... ... group of architectural, engineering, and construction (AEC) experts with building owners and managers ... England. The fourth-annual Create + Construct symposium comes to Boston for the first ...
(Date:7/31/2018)... ... July 31, 2018 , ... Leading regenerative veterinary medicine company, ... and using adipose tissue-derived stem cells to treat or prevent inflammation at the ... covers Canada specifically, VetStem has been issued similar patents that cover the United ...
(Date:7/26/2018)... ... July 26, 2018 , ... Ariadne Afaganis, ... a biofield energy treated nutraceutical to improve anti-inflammatory and immune function responses. , ... in the preclinical research, were significantly reduced. Results are as follows:, ...
Breaking Biology Technology:
(Date:8/2/2018)... ... August 02, 2018 , ... ... in our Austin office, has been named Practice Group Chair for the Pharmaceuticals ... to help continue growing Dickinson Wright’s healthcare and life sciences initiatives, and appreciate ...
(Date:8/1/2018)... ... August 01, 2018 , ... RURO, Inc., a company ... 7.1. Limfinity® is the software framework that all of RURO’s products are built ... current users and the future of RURO’s laboratory software portfolio. , To accommodate ...
(Date:7/31/2018)... DIEGO (PRWEB) , ... July 31, 2018 , ... ACEA ... analysis. The company has just introduced the xCELLigence RTCA S16, which the ... and monitored via an external computer, the S16can be placed in any standard CO2 ...
Breaking Biology News(10 mins):